A recombinant soluble LDL receptor fragment can neutralize minor group rhinovirus infectivity in vitro via aggregation.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for soluble receptor antivirals against minor-group HRVs; leaves open in vivo efficacy and clinical translation.
Marlovits et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: